Open Access Open Access  Restricted Access Access granted  Restricted Access Subscription or Fee Access

No 3 (2012)

Articles

GLUCAGON-LIKE PEPTIDE-1: FROM PHYSIOLOGY TO EFFECTIVE MANAGEMENT OF TYPE 2 DIABETES MELLITUS

Antsiferov M.B., Antsiferov M.B.

Abstract

In recent years, scientific developments have allowed to thoroughly examine the role of incretin hormones in the regulation of carbohydrate metabolism in the human body and their effect on β-cells, as well as create a new area of pharmacotherapy for type 2 diabetes mellitus. An analysis of the results of several direct comparative studies of different incretin drugs is presented. Today, liraglutide (Victoza) shows high clinical efficacy and safety in comparison with other available incretin preparations.
Pharmateca. 2012;(3):9-15
pages 9-15 views

SITAGLIPTIN: CURRENT POSITIONS AND PROSPECTS FOR THERAPY OF TYPE 2 DIABETES MELLITUS

Druk I.V., Nechaeva G.I., Korennova O.Y., Druk I.V., Nechayeva G.I., Korennova O.Y.

Abstract

The article considers the mechanisms of action and potentials for use of dipeptidyl peptidase-4 inhibitor sitagliptin in different variants of diabetes mellitus (DM). It is emphasized that sitagliptin is the most studied drug of gliptin class, allowing control of glycemia at low risk of hypoglycemia, with neutral effect on body weight and good tolerability. Its use is pathogenetically substantiated not only in the early stages of DM2, but also in long-term experience of the disease, including those against the background of insulin therapy. Pleiotropic effects unrelated to effects on glycemia, and tolerability of sitagliptin (potential cardioprotective effects, immunomodulatory effects) offer the prospects for its use in special groups of patients - with cardiovascular diseases, DM1 and post-transplantation diabetes.
Pharmateca. 2012;(3):16-21
pages 16-21 views

TYPE 2 DIABETES MELLITUS AND CONCOMITANT DISEASES: ADVANTAGES OF USE OF DIPEPTIDYL PEPTIDASE-4 INHIBITOR SAXAGLIPTIN (ONGLYZA ®)

Antsiferov M.B., Petunina N.A., Antsiferov M.B., Petunina N.A.

Abstract

The main objective of the treatment of type 2 diabetes mellitus (DM2) is achievement of optimal glycemic control, which significantly reduces the risk of severe complications due to chronic hyperglycemia. However, the management of DM2 patients is associated with a number of problems caused by its frequent combination with other diseases such as obesity, chronic kidney disease, nonalcoholic fatty liver disease, and cardiovascular diseases. In this situation, the doctor is often faced with the choice of antihyperglycemic therapy, since the presence of concomitant diseases limits the administration of a number of oral antihyperglycemic drugs. From this point of view, dipeptidyl peptidase-4 inhibitor saxagliptin is of interest, which is characterized by effective reducing blood glucose levels, low risk of hypoglycemia, no increased risk of cardiovascular disease and a neutral effect on body weight. This provides a broad prospects for application of saxagliptin in DM2 patients with concomitant diseases of the kidneys, liver and cardiovascular system.
Pharmateca. 2012;(3):22-28
pages 22-28 views

APPLICATION OF VILDAGLIPTIN IN COMBINATION WITH INSULIN IN TYPE 2 DIABETES MELLITUS

Antsiferov M.B., Antsiferov M.B.

Abstract

Currently, the prevalence of type 2 diabetes mellitus (DM2) progressively increases. Along with the progression of diabetes mellitus, need for insulin inevitably arises in connection with the deterioration of β-cell function. Insulin therapy allows to maintain more stringent target levels of blood glucose, but is associated with some side effects, the most serious of which are hypoglycemia and body weight gain. They significantly reduce the quality of life of patients and limit their daily activities. In addition, it was shown that hypoglycemia is independent predictor of high risk of cardiovascular mortality and morbidity. The most difficult problem in the treatment of DM2 patients receiving insulin is the risk of severe hypoglycemia. Therapy based on incretinomimetics, which include dipeptidyl peptidase-4 inhibitors (vildagliptin, etc.), can be considered as pathogenetically substantiated choice for these patients. Drugs of this group are characterized by favorable tolerability and high efficacy, their use is associated with lower risk of hypoglycemia. The results of studies on evaluating the efficacy and safety of vildagliptin added to insulin therapy in DM2 patients are presented.
Pharmateca. 2012;(3):29-33
pages 29-33 views

SULFONYLUREAS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS TODAY. IS THERE A PROSPECT?

Kononenko I.V., Smirnova O.M., Smirnova O.M., Kononenko I.V.

Abstract

Despite significant advances in the study of the pathophysiology of type 2 diabetes mellitus and numerous publications in its treatment, there is a large gap between well-established recommendations for its treatment and authentically known remote results of long-term use of drugs. The article analyzes the results of numerous studies on the efficacy and safety of different groups of antihyperglycemic drugs and their comparisons, as well as algorithms for their administration. Common point of view, however, has not yet developed. In all diabetes congresses and in the literature different recommendations are discussed, but the issue of positioning of certain drugs is still open.
Pharmateca. 2012;(3):34-42
pages 34-42 views

HOW TO EFFECTIVELY MANAGE TWO MAJOR DEFECTS IN TYPE 2 DIABETES MELLITUS?

Biryukova E.V., Antsiferov M.B., Biryukova Y.V., Antsiferov M.B.

Abstract

The article considers the modern views on the pharmacotherapy of type 2 diabetes mellitus (DM2). The mechanisms of action of metformin and sulfonylureas from the standpoint of the pathogenesis of the disease are discussed. Particular attention is paid to the combined therapy of DM2. The results of comparative studies of efficacy and safety of fixed combinations of metformin with different sulfonylureas are presented. By the example of drug Amaryl-M, high efficacy of fixed combination (glimepiride + metformin) is shown, which is achieved due to the effect on two major pathogenetic defects in DM2. The potentials for use of this drug in patients of various categories are discussed.
Pharmateca. 2012;(3):43-48
pages 43-48 views

SUSTAINED-RELEASE METFORMIN (GLUCOPHAGE LONG) IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS

Nikonova T.V., Nikonova T.V.

Abstract

Metformin is first-line drug in the treatment of type 2 diabetes mellitus. Original metformin Glucophage is successfully applied in practice for over 50 years. However, adverse effects on the gastrointestinal tract are common in patients receiving metformin; furthermore, they cause discomfort and in some cases require withdrawal of drug. An innovative form of sustained-release metformin (Glucophage Long®), which is based on a dual polymer matrix (system of diffusion through the gel barrier), allows the effective control of glycemia within 24 hours while taking the drug once a day and provides better tolerability compared with the conventional metformin. This new dosage form can improve patients' adherence to metformin.
Pharmateca. 2012;(3):49-52
pages 49-52 views

TIMELY ADMINISTRATION OF INSULIN THERAPY IN TYPE 2 DIABETES MELLITUS

Chernikova N.A., Prudnikova M.A., Chernikova N.A., Prudnikova M.A.

Abstract

The article considers the variants of the start of insulin therapy in patients with type 2 diabetes mellitus (DM2), which failed to reach target glycemic control against the background of uses of oral hypoglycemic drugs and lifestyle modifications. The features of different types of basal insulins are discussed. The advantages of use of long-acting insulin analogue glargine for the initiation of insulin therapy in DM2 patients are described. Simple algorithm for titration of doses, convenient mode of administration (once a day), and reduction of the risk of hypoglycaemia, improvement of glycemic control, improvement of health and quality of life allow to recommended insulin glargine for the start of insulin therapy in these patients.
Pharmateca. 2012;(3):53-57
pages 53-57 views

HOW TO OVERCOME THE EFFECTS OF "HYPERGLYCEMIC" MEMORY?

Biryukova E.V., V Biryukova Y.

Abstract

The article considers the questions of pathogenetic therapy of diabetic polyneuropathy. Pharmacological characteristics of thiamine and its fat-soluble analogue benfotiamine are discussed. Particular attention is paid to mechanisms of action of benfotiamine from a perspective of "hyperglycemic" memory. The results of clinical evaluation of efficacy and safety of benfotiamine are presented. By the example of Milgamma compositum (benfotiamine+pyridoxine) and Milgamma (B1, B6 and B12), high clinical efficacy of a combination of B vitamins is shown; potentials for their administration for the treatment of diabetics depending on the clinical course of distal polyneuropathy are discussed.
Pharmateca. 2012;(3):58-62
pages 58-62 views

PAIN AND ITS FEATURES IN OSTEOPOROSIS

Doskina E.V., Doskin A.V., Doskina Y.V., Doskin A.V.

Abstract

The article discusses the current data on the characteristics and gender differences of pain syndromes (PS) of different origin. The potentials for use of calcitonin in analgesic therapy of osteoporosis are considered. 127 case records of patients with verified osteoporosis were analyzed for the purpose of definition of features of disease in men and women, presence of PS and options for its treatment. The results of use of domestic drug calcitonin (Veprena) in the group of 23 men and women with osteoporosis are presented. It is shown that the Veprena (calcitonin) is a safe and effective drug for the treatment of PS in men and women with osteoporosis. The analgesic effect of the drug Veprena develops after the first intranasal administration, stable therapeutic effect is achieved within 3 months.
Pharmateca. 2012;(3):63-66
pages 63-66 views

DIABETES IN CHILDREN AND ADOLESCENTS: TO THE 90TH ANNIVERSARY OF THE INTRODUCTION OF INSULIN IN CLINICAL PRACTICE

Peterkova V.A., Peterkova V.A.

Abstract

According to the modern concept, type 1 diabetes mellitus (DM1) is an autoimmune disease with a genetic predisposition. Currently, management of DM1 patients includes insulin therapy, self-control, education and physical activity. The article considers the problem of DM1 in children. The insulin preparations used for insulin therapy in children, treatment regimens and devices for insulin administration (syringe insulin delivery systems, pumps), target levels of carbohydrate metabolism in relation to age, as well as principles of assessment of DM1 compensation are discussed. Non-immune forms of diabetes, which are increasingly diagnosed due to the introduction into clinical practice of molecular diagnostics, are represented.
Pharmateca. 2012;(3):67-74
pages 67-74 views

PLACE OF DIBCOR® IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS AND METABOLIC SYNDROME

Vorokhobina N.V., Kuznetsova A.V., Vorohobina N.V., Kuznetsova A.V.

Abstract

The article is dedicated to the role of taurine in the human body, the possibility of therapeutic use of Dibicor ®, a taurine-based drug, including diabetic patients. The results of use of Dibicor ® in the complex therapy of patients with type 2 diabetes mellitus (DM2) and metabolic syndrome (MS) are presented. Study involving 40 patients has shown that inclusion of Dibicor ® at a dose of 0.5 g 2 times daily in the treatment regimen has contributed to the decline in body mass index, lower waist and hips circumferences and improvement of carbohydrate and lipid metabolism (significant reduction in glycated hemoglobin, fasting glucose, total cholesterol, triglyceride and low density lipoprotein cholesterol levels) in patients with DM2 and MS.
Pharmateca. 2012;(3):75-80
pages 75-80 views

THE USE OF CABERGOLINE IN CHILDREN AND ADOLESCENTS WITH HYPERPROLACTINEMIA SYNDROME

Zhurtova I.B., Strebkova N.A., Zhurtova I.B., Strebkova N.A.

Abstract

Prolactin secreting tumors are very rare among children, than in adults. Although treatment strategies for prolactinomas in adults are well established and at present time the preference is given to dopamine agonists, the use of these drugs in pediatric patients is limited due to lack of information on safety and efficiency in this group of patients. Cabergoline is a drug of choice for treatment adult patients with prolactinomas. This clinical material demonstrates high efficacy and good tolerability of cabergoline in children and adolescents with prolactinomas and idiopathic hyperprolactinemia. It will allow in future to refrain from surgical treatment and reduce the number of patients with postoperative complications.
Pharmateca. 2012;(3):81-85
pages 81-85 views

FEATURES OF THE REPRODUCTIVE SYSTEM AND MENOPAUSAL PERIOD IN WOMEN WITH ACROMEGALY

Dreval' A.V., Logutova L.S., Zaydieva Y.Z., Perfil'ev A.V., Chechneva M.A., Ilovayskaya I.A., Dreval A.V., Logutova L.S., Zaydieva Y.Z., Perfilyev A.V., Chechneva M.A., Ilovayskaya I.A.

Abstract

According to the register of patients with acromegaly in Moscow region and other international epidemiological studies, acromegaly predominates among women aged 50 years and over. The article presents the results of evaluation of 34 postmenopausal women with acromegaly. All women of represented group experienced various gynecological diseases. The prevalence of hysteromyoma was 77.8%; high incidence of urogenital disorders (51.8%) was observed. The severity of the climacteric syndrome was assessed using the Green Scale; it was found that menopausal symptoms are similar to the clinical manifestations of acromegaly (eg, headache, fatigue, muscle and joint pain, tachycardia, night sweats, rough breathing). For this reason, Green Scale for the assessment of severity of climacteric syndrome, probably, is not suitable for women with acromegaly.
Pharmateca. 2012;(3):86-89
pages 86-89 views

USE OF MAGNESIUM-CONTAINING DRUG FOR THE TREATMENT OF PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA

Kiseleva O.A., Iomdina E.N., Vasilenkova L.V., Aref'eva M.V., Arutyunyan L.L., Kiseleva O.A., Iomdina Y.N., Vasilenkova L.V., Aref'eva M.V., Arutyunyan L.L.

Abstract

The article presents the data on magnesium deficiency in the media and tissues of glaucoma eyes which constitute a ground for inclusion of the magnesium-containing drug Magnerot (magnesium orotate) in the complex treatment of patients with primary open-angle glaucoma (POAG). The first results of the use of drug have shown its beneficial effects on the structural and functional state of the glaucoma eyes: significant reduction in intraocular tension and improvement of hydrodynamics in glaucoma eyes, as well as positive dynamics of the visual field and retinotomography parameters depending on the initial state (POAG stage) were observed. This study demonstrates the prospects for use of Magnerot in combination drug therapy of glaucoma optic neuropathy and the need for further comprehensive study of its clinical effectiveness.
Pharmateca. 2012;(3):90-95
pages 90-95 views

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies